echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Immuno Cancerl Immunother: Effects of tumor immunotromystology on patients with leukocyte hyperemia

    Immuno Cancerl Immunother: Effects of tumor immunotromystology on patients with leukocyte hyperemia

    • Last Update: 2020-05-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Tumor-related leukaemia (TRL) is associated with poor survivability of various types of cancer, but the microenvironment of TRL-related human tumors has not yet been fully clarifiedHere, we aim to describe the immune microenvironment of TRL-related cancer patientsstudies compared the transcriptional characteristics of tumor tissue (TRLpos) obtained from patients with cervical cancer and the transcriptional characteristics of tumor tissue without TRL (TRLneg)As a substitute for TRL diagnosis, a white blood cell hyperplasia (LS) score was obtained using different genes expressed between TRLpos and TRLneg tumorsThe immunological spectrum of patients with high (LShigh) or low LS scores in the TCGA database was comparedresults showed that there were differences in transcription between TRLpos tumors and TRLneg tumors, showing genes associated with upward radiation resistance and reduced adaptive immune responseIn the TCGA cervical cancer queue (n s 303), patients with high LS had a lower survival rate (P s 0.023) compared to patients with low LSLShigh tumors have higher levels in radiation resistance, wound healing, and myelin-like inhibition (MDSC) markers, M2 macrophages are more immersion, and M1 macrophages and lymphocyte leachate are lowerLShigh tumors also expressed higher CXCR2 towardsther, CSF2, and CSF3In the pan-cancer cohort (n - 9984), LShigh tumors also showed poor survival, characteristics of inhibitory immune microenvironments and higher expression of CXCR2 prosthesis factorsin summary, our data provide evidence for inhibitory immunoimmune microenvironments in Patients of TRL and present promising targets, such as CXCR2 axes, for therapeutic intervention
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.